Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of rivaroxaban 10 mg tablet formulations in healthy Thai volunteers under fasted conditions
TCTR20190430003Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban (2 arms), sponsored by Novartis. Primary endpoints: Cmax, AUC0-t and 2 more. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
rivaroxaban
Beyond the preview
Go deeper on TCTR20190430003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190430003.